These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 9145227)

  • 1. Urinary excretion of mefenamic acid and its metabolites including their esterglucuronides in preterm infants undergoing mefenamic acid therapy.
    Sato J; Kudo N; Owada E; Ito K; Niida Y; Umetsu M; Kikuta T; Ito K
    Biol Pharm Bull; 1997 Apr; 20(4):443-5. PubMed ID: 9145227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of mefenamic acid in preterm infants with patent ductus arteriosus.
    Ito K; Niida Y; Sato J; Owada E; Ito K; Umetsu M
    Acta Paediatr Jpn; 1994 Aug; 36(4):387-91. PubMed ID: 7942001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary ET-1, AVP and sodium in premature infants treated with indomethacin and ibuprofen for patent ductus arteriosus.
    Zanardo V; Vedovato S; Lago P; Trevisanuto D; Favaro F; Faggian D; Plebani M
    Pediatr Nephrol; 2005 Nov; 20(11):1552-6. PubMed ID: 16133044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy of symptomatic patent ductus arteriosus in preterms using mefenemic acid and indomethacin.
    Sakhalkar VS; Merchant RH
    Indian Pediatr; 1992 Mar; 29(3):313-8. PubMed ID: 1612672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary aquaporin-2 excretion during ibuprofen or indomethacin treatment in preterm infants with patent ductus arteriosus.
    Li Y; Zelenina M; Plat-Willson G; Marcoux MO; Aperia A; Casper C
    Acta Paediatr; 2011 Jan; 100(1):59-66. PubMed ID: 21143292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structures of mefenamic acid metabolites from human urine.
    Sato J; Yamane Y; Ito K; Bando H
    Biol Pharm Bull; 1993 Aug; 16(8):811-2. PubMed ID: 8220331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reopening of the ductus arteriosus in preterm infants; Clinical aspects and subsequent consequences.
    Halil H; Buyuktiryaki M; Atay FY; Oncel MY; Uras N
    J Neonatal Perinatal Med; 2018; 11(3):273-279. PubMed ID: 30149471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reactivity of mefenamic acid 1-o-acyl glucuronide with proteins in vitro and ex vivo.
    McGurk KA; Remmel RP; Hosagrahara VP; Tosh D; Burchell B
    Drug Metab Dispos; 1996 Aug; 24(8):842-9. PubMed ID: 8869817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic closure of the ductus arteriosus: benefits and limitations.
    Mercanti I; Boubred F; Simeoni U
    J Matern Fetal Neonatal Med; 2009; 22 Suppl 3():14-20. PubMed ID: 19925358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral ibuprofen and indomethacin for treatment of patent ductus arteriosus in premature infants: a randomized trial at Ramathibodi Hospital.
    Supapannachart S; Limrungsikul A; Khowsathit P
    J Med Assoc Thai; 2002 Nov; 85 Suppl 4():S1252-8. PubMed ID: 12549803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacologic Treatment of Patent Ductus Arteriosus in the Preterm Infant.
    Gregory KE
    J Perinat Neonatal Nurs; 2016; 30(1):6-8. PubMed ID: 26813387
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparative Effectiveness of Nonsteroidal Anti-inflammatory Drug Treatment vs No Treatment for Patent Ductus Arteriosus in Preterm Infants.
    Slaughter JL; Reagan PB; Newman TB; Klebanoff MA
    JAMA Pediatr; 2017 Mar; 171(3):e164354. PubMed ID: 28046188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of enteral formulations of ibuprofen in the treatment of patent ductus arteriosus in preterm infants.
    Gouyon JB; Kibleur Y
    Clin Ther; 2010 Sep; 32(10):1740-8. PubMed ID: 21194597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New therapeutic strategies for the treatment of patent ductus arteriosus in preterm infants.
    Dani C
    J Matern Fetal Neonatal Med; 2011 Nov; 24 Suppl 3():5-6. PubMed ID: 21815877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and side effects of an escalating, stepwise approach to indomethacin treatment for symptomatic patent ductus arteriosus in premature infants below 33 weeks of gestation.
    Sperandio M; Beedgen B; Feneberg R; Huppertz C; Brüssau J; Pöschl J; Linderkamp O
    Pediatrics; 2005 Dec; 116(6):1361-6. PubMed ID: 16322159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Echocardiography as a guide for patent ductus arteriosus ibuprofen treatment and efficacy prediction.
    Desandes R; Jellimann JM; Rouabah M; Haddad F; Desandes E; Boubred F; Semama DS; Vieux R; Hascoët JM
    Pediatr Crit Care Med; 2012 May; 13(3):324-7. PubMed ID: 21760564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis, Biological Evaluation and Pharmacokinetic Studies of Mefenamic Acid - N-Hydroxymethylsuccinimide Ester Prodrug as Safer NSAID.
    Husain A; Ahuja P; Ahmad A; Khan SA
    Med Chem; 2016; 12(6):585-91. PubMed ID: 26740206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary excretion rates of 6-keto-PGF1 alpha in preterm infants recovering from respiratory distress with and without patent ductus arteriosus.
    Seyberth HW; Müller H; Ulmer HE; Wille L
    Pediatr Res; 1984 Jun; 18(6):520-4. PubMed ID: 6588360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensive and prolonged urine collection in preterm infants reveals three distinct indomethacin metabolic patterns: potential implications for drug dosing.
    Lewis T; Van Haandel L; Scott A; Leeder JS
    Pediatr Res; 2018 Sep; 84(3):325-327. PubMed ID: 29967531
    [No Abstract]   [Full Text] [Related]  

  • 20. Present and future of European neonatology: focus on patent ductus arteriosus.
    Fanos V; Guimarâes H
    J Matern Fetal Neonatal Med; 2009; 22 Suppl 3():1-2. PubMed ID: 19925356
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.